Since CD45+CD11b+Ly6G− populations primarily contain monocytes and macrophages, our results suggest that the CCL2 KO MSCs promote anti-tumor responses via mononuclear myeloid cell-mediated pathways in the TME. The gene discussed is CCL2; the disease is neoplasm.